04 March 2021 | EventsNCIRS COVID-19 vaccine webinar series - register now for March webinarsRead the full article
NCIRS is co-leading the Australian COVID-19 Serosurveillance Network and a suite of serosurveys with the Kirby Institute to measure the prevalence of antibodies to SARS-CoV-2 in target populations. Serosurveys involve conducting serological tests on thousands of Australians across various age groups, geographical locations and target populations to determine whether someone has been exposed to SARS-CoV-2. The tests detect antibodies, which are made by the body following an infection with the virus. SARS-CoV-2 serosurveys provide critical information to estimate the spread of the 2019 novel coronavirus in the Australian community. Currently our understanding of the epidemiology of COVID-19 in Australia has been predominantly based on the identification of cases who have presented for testing because they are ill (have symptoms). While this allows us to see the “tip of the iceberg”, seroprevalance studies provide a broader view of previous SARS-CoV-2 infections, including mild and asymptomatic cases and those who may not have been tested during their infection.
SARS-CoV-2 serosurveys are a key component of the Australian National Disease Surveillance Plan for COVID-19 and are listed as a precedent condition necessary to inform public health measures in the Australia’s Pandemic Health Intelligence Plan. Findings from these serosurveys will be used to inform public health policy, vaccination strategies and mathematical models designed to predict future disease spread, associated morbidity and mortality, health service needs and COVID-19 vaccine introduction.
Three serosurveys are currently underway, led by NCIRS and the Kirby Institute and involving many collaborators:
The national and paediatric serosurveys are funded in part by the APPRISE CRE and the Snow Medical Foundation, and are being undertaken in alignment with the Australian National Disease Surveillance Plan for COVID-19. The Australian COVID-19 Serosurveillance Network involves collaboration between public and private laboratories, Australian Red Cross Lifeblood, national and jurisdictional health department representatives and subject matter experts (see the below list). This network has been established to bring together collaborators and expertise, and facilitate the ability to draw on the same sites to repeat serosurveys at subsequent times.
Lead investigator team
Key collaborators and funding bodies
Laboratory methods leads
We acknowledge and thank other collaborators involved, including those not specifically named above.
NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090
We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Copyright © 2021 NCIRS. All rights reserved
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.
Stay updated with the latest from NCIRS